For people living with type 2 diabetes, protecting kidney health is often a lifelong challenge.
Diabetes is one of the leading causes of chronic kidney disease, and many patients also develop high blood pressure. Together, these conditions can gradually damage the kidneys and increase the risk of serious complications.
Over the last decade, doctors have gained powerful new tools to slow kidney damage. Newer medications have helped many patients keep their kidneys working longer and avoid kidney failure. However, new research suggests that one of the most frequently prescribed blood pressure medicines may deserve a closer look.
Scientists recently presented their findings at the 63rd ERA Congress. They investigated the effects of dihydropyridine calcium-channel blockers, a popular group of blood pressure medicines commonly used when initial treatments are not enough to control blood pressure.
High blood pressure is especially harmful in people with diabetic kidney disease because it places extra strain on already damaged kidneys. Doctors often prescribe multiple medications to keep blood pressure under control. DCCBs have been widely used for many years because they effectively lower blood pressure and are generally considered safe.
The study included more than 31,000 adults with type 2 diabetes. All participants were receiving two types of medications that are now considered standard care for diabetic kidney disease.
These included RAS inhibitors, which help reduce pressure inside the kidneys, and SGLT2 inhibitors, which have become well known for protecting kidney function and lowering the risk of kidney failure.
Researchers divided participants based on the blood pressure medicines they were taking. About four out of every ten patients were using DCCBs, while the remaining participants were taking different blood pressure treatments. The team then monitored kidney health outcomes over several years.
When the results were analyzed, a concerning pattern appeared. Patients using DCCBs experienced more serious kidney-related problems than those taking alternative medications. After accounting for differences between patients, researchers found a 33% higher risk of major kidney events among DCCB users.
Major kidney events included a substantial decline in kidney function or progression to severe kidney disease requiring dialysis or a kidney transplant. These outcomes are among the most serious complications faced by people with diabetic kidney disease.
Scientists believe the explanation may lie in the way blood flows through the kidneys. Healthy kidneys filter enormous amounts of blood every day through tiny filtering structures.
In diabetic kidney disease, these structures are already vulnerable. Researchers suggest that DCCBs may affect blood vessels entering the filtering units differently from those leaving them. This imbalance could increase pressure inside the filters and potentially contribute to long-term damage.
What surprised the researchers most was that the increased risk appeared even among patients receiving modern kidney-protective medicines. Many experts expected the protective effects of SGLT2 inhibitors to reduce or eliminate any potential concerns. Instead, the association remained visible throughout the study.
The researchers stress that patients should not stop taking prescribed medications based on this study alone. The research does not prove that DCCBs directly cause kidney damage. Because the study observed real-world patients rather than randomly assigning treatments, other hidden factors could have influenced the results.
Still, the findings are important because DCCBs are prescribed to millions of people worldwide. If future research confirms the results, doctors may need to rethink treatment strategies for patients with diabetic kidney disease.
The study highlights how medical knowledge continues to evolve. Treatments once considered equally effective may have different long-term effects in specific groups of patients. As researchers learn more about how medications interact with kidney disease, doctors can make more informed decisions and potentially improve patient outcomes.
Analysis of the findings suggests this study serves as an early warning signal rather than definitive proof. The large patient population and lengthy follow-up period make the results difficult to ignore. However, randomized controlled trials will be needed before treatment guidelines change.
Until then, the study encourages doctors and researchers to carefully evaluate whether all blood pressure medications provide the same level of kidney protection in people with type 2 diabetes. The research may eventually lead to safer and more effective treatment plans for patients at risk of kidney failure.
If you care about high blood pressure, please read studies that early time-restricted eating could help improve blood pressure, and natural coconut sugar could help reduce blood pressure and artery stiffness.
For more information about blood pressure, please see recent studies about How to eat your way to healthy blood pressure and results showing that Modified traditional Chinese cuisine can lower blood pressure.
The findings were presented at the 63rd ERA Congress.
Source: ERA Congress.
